-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Cin1DcPGoQd/Rk7ok+B0g5DotuMeu+LFtQOS1fXXiRFarviMY/hZ0HOasEkCJ87e rUygDnZgsYYLGfU2k0VfZg== 0000950005-96-000367.txt : 19960719 0000950005-96-000367.hdr.sgml : 19960719 ACCESSION NUMBER: 0000950005-96-000367 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19960613 ITEM INFORMATION: Other events FILED AS OF DATE: 19960613 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIDAMED INC CENTRAL INDEX KEY: 0000929900 STANDARD INDUSTRIAL CLASSIFICATION: 3841 IRS NUMBER: 770314454 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26082 FILM NUMBER: 96580470 BUSINESS ADDRESS: STREET 1: 1380 WILLOW ROAD STREET 2: SUITE 101 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 4153288781 MAIL ADDRESS: STREET 1: 1300 WILLOW RD STREET 2: STE 101 CITY: MENLO PARK STATE: CA ZIP: 94025 8-K 1 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 1996 VIDAMED, INC. (exact name of registrant as specified in its charter) Delaware 0-26082 77-0314454 (State or other jurisdiction of (Commission File No.) (IRS Employer incorporation or organization) Identification No.) 1380 Willow Road, Suite 101 Menlo Park, CA 94025 (Address of principal executive offices) (415) 328-8781 (Registrant's telephone number, including area code) Page 1 of 6 Item 5. Other Events VidaMed, Inc. (the "Company") is filing unaudited interim financial statements at and for the period ended April 30, 1996 to demonstrate that the Company is in compliance with the continuing listing standards of the Nasdaq National Market. Such financial statements are attached hereto as exhibit 99.1. Item 7. Financial Statements and Exhibits (c) Exhibits 99.1 Balance Sheet of the Company at April 30, 1996 and Statement of Operations of the Company for the four months ended April 30, 1996. Page 2 of 6 Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIDAMED, INC. By: /s/ James A. Heisch ------------------------------- James A. Heisch, President and Chief Executive Officer Page 3 of 6 EXHIBIT INDEX Exhibit No. Description ----------- ----------- 99.1 Balance Sheet of the Company at April 30, 1996 and Statement of Operations of the Company for the four months ended April 30, 1996. Page 4 of 6 EX-99.1 2 BALANCE SHEET OF THE COMPANY AT 4/30/96 EXHIBIT 99.1 VidaMed, Inc. Condensed Consolidated Balance Sheets
April 30, March 31, 1996 1996 ------------ ------------ Assets Current Assets: Cash and cash equivalents $ 7,210,385 $ 11,144,937 Short-term investments 8,887,100 5,913,200 Other current assets 1,907,840 2,338,517 ------------ ------------ Total current assets 18,005,325 19,396,654 Property and equipment, net 2,823,907 2,863,987 Other assets, net 227,674 232,289 ------------ ------------ Total assets $ 21,056,906 $ 22,492,930 ============ ============ Liabilities and stockholders' equity Current liabilities: Notes payable, current portion $ 986,474 $ 977,239 Accounts payable 623,046 442,197 Accrued compensation 255,289 252,071 Accrued professional fees 295,969 251,254 Accrued clinical trial costs 879,849 886,394 Accrued and other liabilities 2,955,843 2,948,200 Deferred revenue 637,500 672,917 ------------ ------------ Total current liabilities 6,633,970 6,430,272 Notes payable, noncurrent 1,201,814 1,288,339 Convertible notes, noncurrent 1,050,000 10,100,000 Other long-term liabilities 978,882 1,023,929 Stockholders' equity: Capital stock 53,996,634 45,313,534 Accumulated deficit (42,804,394) (41,663,144) ------------ ------------ Total stockholders' equity 11,192,240 3,650,390 ------------ ------------ Total Liabilities and stockholders' equity $ 21,056,906 $ 22,492,930 ============ ============
Page 5 of 6 VidaMed, Inc. Condensed Consolidated Statements of Operations Four Months Ended April 30, 1996 ------------- Revenues: Product sales, net $ 459,693 License fees and grant revenue 143,316 ------------- Net revenues 603,009 Operating Expenses: Cost of product sales 974,567 Research and development 1,848,787 Selling, general and administrative 2,224,133 ------------ Total operating expenses 5,047,487 ------------ Loss from operations (4,444,478) Other expense, net (27,128) ------------ Net loss $(4,471,606) ============ Page 6 of 6 -----END PRIVACY-ENHANCED MESSAGE-----